机译:高剂量治疗多发性骨髓瘤患者美法仑的群体药代动力学
The Children's Hospital at Westmead,;
The Children's Hospital at Westmead,|University of Sydney, Sydney, NSW, Australia and;
Concord Hospital,;
The Children's Hospital at Westmead,;
University of Otago, Dunedin, New Zealand;
University of Otago, Dunedin, New Zealand;
Concord Hospital,|University of Sydney, Sydney, NSW, Australia and;
Westmead Hospital,;
Westmead Hospital,;
Concord Hospital,;
Wollongong Hospital,;
Gosford Hospital,;
Royal Prince Alfred Hospital,;
The Children's Hospital at Westmead,;
melphalan; myeloma; optimal dosing; population pharmacokinetics; transplantation;
机译:接受高剂量治疗的多发性骨髓瘤患者中美法仑的群体药代动力学。
机译:大剂量多发性骨髓瘤患者中美法仑的群体药代动力学
机译:临床药代动力学检测方法的发展,以允许靶向梅酚给药在经历自体移植的多发性骨髓瘤患者中
机译:使用化学疗法的单中心经验与Melphalan-Dexamethasone(M-DEX)的Al淀粉样蛋白病和先进器官参与没有资格获得高剂量Melphalan治疗(HDM)
机译:使用群体药代动力学/药效学方法,与非肥胖患者相比,肥胖患者的β-内酰胺抗菌药物剂量优化。
机译:高剂量治疗多发性骨髓瘤患者美法仑的群体药代动力学
机译:高剂量治疗多发性骨髓瘤患者美法仑的群体药代动力学